H U M A N G E N E T H E R A P Y 9:2577-2583 (November 20, 1998) Mary Ann Liebert, Inc.
Efficient C o n s t r u c t i o n o f a R e c o m b i n a n t A d e n o v i r u s V e c t o r
b y a n I m p r o v e d In Vitro Ligation M e t h o d
HIROYUKI MIZUGUCHli-2 and MARK A. KAY'
ABSTRACT
A n efficient method for constructing a recombinant adenovirus (Ad) vector, based on an in vitro ligation, has
been developed. T o insert the foreign gene into an adenoviral D N A , we introduced three unique restriction
sites, l-Ceu\, Swal, and Pl-Scel, into the El deletion site of the vector plasmid, which contains a complete El,
E3-deleted adenovirus type 5 genome. \-Ceu\ and Pl-Scel are intron-encoded endonucleases with a sequence
specificity of at least 9-10 and 11 bp, respectively. A shuttle plasmid, p H M 3 , containing multiple cloning sites
between the \-Ceu\ and ¥\-Scel sites, was constructed. After the gene of interest was inserted into this shut
tle plasmid, the plasmid for El-deleted adenovirus vector could be easily prepared by in vitro ligation using
the \-Ceul and Pl-Scel sites. Swal digestion of the ligation products prevented the production of a plasmid
containing a parental adenovirus genome (null vector). After transformation into E. coli, more than 9 0 % of
the transformants had the correct insert. T o m a k e the vector, a jPacI-digested, linearized plasmid was trans
fected into 293 cells, resulting in a homogeneous population of recombinant virus. The large number and
strategic location of the unique restriction sites will not only increase the rapidity of production of new first-
generation vectors for gene transfer but will allow for rapid further improvements in the vector D N A back
bone.
OVERVIEW SUMMARY
One of the limitations of recombinant adenovirus vectors is their construction, which is a time-consuming procedure. This study demonstrates that the plasmid containing recombinant adenovirus D N A can be prepared by a simple in vitro ligation using three unique restriction sites, I-C^mI, Swal, and Pl-Scel, in the El deletion region. P a d digestion of the recombinant plasmid generates the D N A for adenovirus vector, which has an inverted terminal repeat at both ends of the genome. Homogeneous recombinant virus could be obtained by the transfection of the linearized plasmid into 293 cells. This improved in vitro ligation system is a simple and efficient method by which to construct a recombinant adenovirus vector for gene therapy.
INTRODUCTION
RECOMBINANT ADENOVIRUS VECTORS havc been shown to have great promise for gene transfer in basic research as
well as for clinical treatment of many diseases (Kozarsky and
Wilson, 1993; Kay and Woo, 1994). They can transduce foreign genes efficiently into both cultured cells and many target organs in vivo. There are more than 40 serotypes of adenovims (Ad) identified. The Ad type 5 genome has been used most commonly to make recombinant Ad vector. The genome of human Ad is a linear 36-kb, double-stranded D N A genome that encodes more than 50 gene products. In the first-generation Ad vector, the early region 1 (El) is replaced by the foreign gene and the vims propagated in an El-rran.y-complementing cell line such as 293. By deleting El and early region 3 (E3) sequences up to about 8 kb of foreign gene can be inserted (Bett et al, 1994). However, in vitro manipulation of Ad D N A is difficult. Unique and useful restriction sites are limited because of the large size of the genome, making the constmction of Ad vectors relatively labor intensive. Two standard methods to make El-deleted Ad vectors have been developed: an in vitro ligation method (Berkner and Sharp, 1983; Gilardi et al, 1990; Rosenfeld et al, 1991) and a homologous recombination method in 293 cells (Bett et al 1994; Miyake et al, 1996). The in vitro ligation method uses whole viral D N A genomes and a plasmid containing the left end of the Ad genome with the left inverted terminal repeat (ITR), the packaging signal, and the
'Departments of Pediatrics and Genetics, Stanford University School of Medicine, Stanford, CA 94305. Present address: Division of Biological Chemistry and Biologicals, National Institute of Health Sciences, Tokyo 158. lapan.
2577
Dow
nloa
ded
by S
tanf
ord
Uni
vers
ity M
edic
al C
ente
r fr
om w
ww
.lieb
ertp
ub.c
om a
t 10/
09/1
8. F
or p
erso
nal u
se o
nly.
2578 MIZUGUCHI AND KAY
EIA enhancer sequence (map units 0 to 1.3). After the gene of interest is inserted downstream ofthe viral sequence ofthe plasmid, the fragment containing viral sequence and the gene of interest is excised and ligated into the unique Clal site (map unit 2.6), replacing a portion of the viral El region. Then, the ligated D N A is directly transfected into 293 cells to make recombinant vims. However, this method is rarely used now because the efficiency is low and the recombinant virus requires purification of contaminating wild-type and transgene null vimses related to incomplete restriction digestion and self-reli-gation. One system based on homologous recombination (Bett et al, 1994) uses two plasmids with overlapping fragments that recombine In vivo. The first plasmid contains the entire Ad genome with a deletion of the D N A packaging signal and El region. The second plasmid contains the left ITR, packaging signal, and overlapping sequence with the first plasmid. After the gene of interest is introduced into the second plasmid, the two plasmids are cotransfected into 293 cells. The vims, which is produced by the recombination in 293 cells, is isolated through plaque purification. The major limitation to this approach is that the recombination event occurs at a low frequency.
Newer methods for adenoviral preparation are based on homologous recombination of two plasmids, using yeast artificial chromosomes (YACs; Ketner et al, 1994) or bacteria (Chartier et al, 1996; Crouzet et al, 1997; He et al, 1998). These methods, while more efficient, are more complex. The Y A C system requires yeast culture and manipulation (Ketner et al, 1994), while the Escherichia coli system requires three-step transformations using an additional, nonconventional host bacterial strain (BJ5183recBCsbcBC) (Chartier et al, 1996; Crouzet et al, 1997; He et al, 1998).
In this article we report the efficient constmction of an El-deleted Ad vector by an improved in vitro ligation method. This system requires a simple in vitro ligation using routine molecular biology reagents and transformation in commonly used bacterial strains.
MATERIALS AND METHODS
Plasmids
Vector plasmids pAdHMl, -2, -3, and -4 were constmcted as follows. pHVad2 (provided by HepaVec, Berlin, Germany), which has the left end (bp 1-341 and bp 3524-5790) of the Ad type 5 genome with an El deletion, was cut by Clal and £coRI, and ligated with oligonucleotides 1 (5' CGTAACTATAACG-G T C C T A A G G T A G C G A G 3') and 2 (5' AATTCTCGCTAC-CTTAGGACCGTTATAGTTA 3') (l-Ceiil recognition sequences are underlined), resulting in pAd4. pAd4 was then cut with EcoRI and Sail, and then ligated with oligonucleotides 3 (5' AATTA7Tr/L4ArATCTATGTCGGGTGCGGAGAAA-G A G G T A A T G A A A T G G C A 3!j and 4 (5! TCGATGC-CATTTCATTACCTCTTTCTCCGCACCCGACATA-GAT/4TTTAAAT 3') (Pl-Scel and Swal recognition sequences are underlined and italicized, respectively), resulting in pAdl8, which contains l-Ceul, Swal, and Pl-Scel sites. pAdl9, which contains the Ad type 5 genome (bp 1 to 21562), was prepared by the insertion of the Pad/BamHl fragment of pTG3602
(Chartier et al. 1996), which has a full-length Ad type 5 genome flanked with a Pad site, in the plasmid derived from pGEM7Zfi-) (Promega, Madison, WI). The PadlXcal fragment of pAdl8 and pAdI9 were then ligated, resulting in pAdl6. The BaniHlIPad fragment (bp 21562 to the right end of the genome) of pTG3602 or pHVad I (provided by HepaVec), both of which have the Ad type 5 genome with a deletion in the E3 region (bp 28133-30818), were introduced into the Clal and BamHI sites of pGEM7Zf(-), after the Pad site of pTG3602 and pHVadl was changed into a Clal site by using a Clal linker (New England BioLabs, Beveriy, M A ) , resulting in pAdI and pAd2, respectively. The fragment of pAdl6 digested with Pad and BamHI was then cloned into the Nsil and BamHI sites of pAdl and pAd2, respectively, after the Nsil site was changed into a Pad site by using a Pad linker (New England BioLabs). The resulting plasmids were named pAdHMl and pAdHM2, respectively. The Clal site of pAdHMI and pAdHM2 was changed into a Pad site by using oligonucleotides 5 (5' CGTTAATTAA 3') and 6 (5' CGTTAATTAA 3') (Pad recognition sequences are underlined), resulting in pAdHM3 and pAdHM4, respectively. pAdHMl, -2, -3, and -4 have 1-Ceul, Swal, and PI-5ceI sites in the El deletion region. pAdHMl and -3 have the Ad genome with a deletion in the El region (AEl; bp 342-3523). while pAdHM2 and -4 have the Ad genome with a deletion in the El and E3 regions (AEl, bp 342-3523; AE3, bp 28133-30818). pAdHMl and pAdHM2 have a Pad site at the left end of the Ad genome and a Clal site at the right end of the genome. pAdHM3 and pAdHM4 have Pad sites at both ends of the Ad genome (Fig. lA).
Shuttie plasmid pHM3 was constmcted as follows. pUC18 was cut by AatU and Hindlll, and ligated with oligonucleotides 7 (5' T A A C T A T A A C G G T C C T A A G G T A G C G A A 3') and 8 (5' AGCTTTCGCTACCTTAGGACCGTTATAGTTAACGT 3') (1-Ceul recognition sequences are underlined), resulting in pHMl. pHMl was cut with £coRl and PvuU, and then ligated with oligonucleotides 9 (5' AATTCTGGCAAACAGCTAT-TATGGGTATTATGGGT 3') and 10 (5' ACCCATAATACC-CATAATAGCTGTTTGCCAG 3') (Pl-Pspl recognition sequences are underiined), resulting in pHM2. This plasmid has another intron-coded enzyme (PI-P.spI) recognition site. The Pl-Pspl fragment of pHM2 was then ligated with oligonucleotides 11 (5' AT C T A T G T C G G G T G C G G A G A A A G A G -G T A A T G A A A T G G C A T T A T 3') and 12 (5' TGCCATTT-CATTACCTCTTTCTCCGCACCCGACATAGATATAA 3') (PI-5ceI recognition sequences are underlined). The resulting plasmid was named pHM3 (Fig. IB). pHM3 contains the pUC18-derived multicloning site between the 1-Ceul and Pl-Scel sites. Al! mutations were sequenced with a Sequenase version 2.0 D N A sequencing kit (New England Nuclear, Boston. MA).
Construction of recombinant Ad vector DNA containing human aj-antitiypsin expression cassette
The Xhol fragment of pBSRSVhAAT (Kay et al, 1992), containing the Rous sarcoma virus long terminal repeat (RSV LTR) promoter, human c ,-antitrypsin (hAAT) cDNA, and bovine growth hormone polyadenylation signal, was cloned into the Sail site of pHM3. Depending on the orientation of the hAAT expression cassette, the resulting plasmids were named pHM3-hAATl and pHM3-hAAT2 (Fig. IC).
Dow
nloa
ded
by S
tanf
ord
Uni
vers
ity M
edic
al C
ente
r fr
om w
ww
.lieb
ertp
ub.c
om a
t 10/
09/1
8. F
or p
erso
nal u
se o
nly.
EFFICIENT CONSTRUCTION OF Ad VECTORS 2579
Swal l-Ceul Pl-Scel
; : £ : adenovirus genome
E1(-)(342-3S23)
pAdHMI 33.0 Kb
Swal l-Ceul Pl-Scel
p Clal Pad. ^ \ / adenovin 1 1 ^ i-^ir^
- ^ r - . 1 Amp'
E1(-) (342-3523)
p A d H M 3 33.0 Kb Amp^
Swal l-Ceul Pl-Scel
;4 adenovirus genome
El (-) (342-3623)
p A d H M 2 30.3 Kb
E3(-) (28133-30616) <-
Amp'
Swal l-Ceul Pl-Scel
f Clal Pad fE * , - ^
^ adenovirus genome
El (-) (342-3523)
p A d H M 4 30.3 Kb
E3(-) (26133-30816) ^
Amp^
B
Amp'
l-Ceul Hindlll SphI Pstl Sall'Accl/Hincll Xbal BamHI Smal/Xmal Kpnl Sad EcoRI Pl-Scel
pAdHM4
i
l-Ceul Pl-Scel
Ligation products
i
i
Swal digestion to reduce background
Transformation with DH5a
RSV hAAT bPA
Pad
, Pl-Sael
adenovirus genome
pHM3
hAAT expression cassette
hAAT
Pl-Scel bPA
pAdHWI4-hAAT 32.4 K b
I Pad digestion
Transfection into 293 cells
E3(-) (28133-30818)
Pad
Amp'
F I G 1 Constmction of recombinant adenovirus vectors by a simple in vitro ligation method. (A) Vector plasmids p A d H M l , -2 -3 and -4 (B) Shuttie plasmid p H M 3 . (C) The sttategy for constmction of El- and E3-deleted adenovims vector. The expression cassette of interest ( R S V h A A T b P A ) was inserted into the SaU site of the multicloning site of p H M 3 , and the resulting plasmid p H M 3 - h A A T l was digested with l-Ceul and Pl-Scel. The fragment containmg the h A A T expression cassette was ligated with p A d H M 4 digested with l-Ceul and PI-5ceI. Transformation into D H 5 a was performed after the ligation samples were digested with Swal to reduce the formation of colonies containing parental vector plasmid (pAdHM4).
Dow
nloa
ded
by S
tanf
ord
Uni
vers
ity M
edic
al C
ente
r fr
om w
ww
.lieb
ertp
ub.c
om a
t 10/
09/1
8. F
or p
erso
nal u
se o
nly.
2580 M I Z U G U C H I A N D K A Y
To constmct the plasmid for a recombinant Ad vector expressing hAAT, pHM3-hAATI was digested with I-G?i(I and Pl-Scd. and the fragment containing the h A A T expression cassette was isolated by gel extraction after agarose gel electrophoresis. p A d H M 4 was also digested with l-Ceul and PI-Scel, but the digested D N A was purified by phenol-chloroform extraction and ethanol precipitation. Digested p A d H M 4 (0.1 pg) was then ligated to the p H M 3 fragment containing the h A A T expression cassette at I6°C for more than 2 hr. To reduce the background with the parental plasmid, p A d H M 4 , the ligation products were treated at 65°C for 20 min to inactivate T4 D N A ligase, and then digested with Swal. Swal cuts the parental plasmid (pAdHM4), but not the recombinant plasmid. Finally, the D N A s were transformed with electrocompetent D H 5 a (chemical-competent D H 5 a can be also used), and the individual clones were screened by restriction analysis (Fig. IC). Large-scale preparation of plasmid p A d H M 4 - h A A T was performed by using a Qiagen Plasmid Maxi-kit (Qiagen, Chatsworth, CA). No rearrangement ofthe plasmid during amplification was observed.
Generation of adenovirus vector
p A d H M 4 - h A A T was linearized by the digestion with Pad and purified by phenol-chloroform extraction and ethanol pre-
1 2 3 4 5 6 7 8 9 1011121314
cipitation. The D N A was transfected into subconfluent 293 cells plated in a 60-mm dish with SuperFect (Qiagen) according to the manufacturer's instructions. The cells were cultured with Dulbecco's modified Eagle's medium ( D M E M ) (GIBCO, Grand Island, N Y ) containing 1 0 % fetal calf semm (FCS) or with 0.5% overlaid agarose-DMEM containing 1 0 % FCS. Ten days later, the cells were harvested and five independent plaques were isolated. The virus was released by four cycles of freezing and thawing, and amplified in 293 cells. Recombinant virus expressing h A A T was referred to as AdhAAT. The titer of the vims was measured by standard plaque assay in 293 cells (Kay etal, 1995).
To analyze the viral D N A . Ad D N A was isolated from the cells with full cytopathic effect (CPE) as described previously (Lieber et al. 1996). Briefly, 293 cells with full C P E were digested with 0.1% pronase m )0 m M Tris-HCl (pH 7,5)-l% sodium dodecyl sulfate-10 m M E D T A ovemight at 37°C. After phenol-chloroform extraction, D N A was ethanol precipitated, dissolved in T E (10 niM Tris [pH 7.5]. 1 m M E D T A ) , and digested with Hindlll or I-C(?i(l/PI-5c<?I, and analyzed in a 0.8% agarose gel stained with ethidium bromide.
h/\AT expression in HeLa cells infected with AdhAAT
HeLa cells (8 X 10^ cells) were seeded into a 60-mm dish, and the next day they were treated with A d h A A T (at a multiplicity of infection [MOI] of 20 or 100). The cells were cultured with D M E M containing 1 0 % FCS and 2 days later h A A T concentrations in the medium were determined by enzyme-linked immunosorbent assay as previously described (Kay et al, 1995).
FIG. 2. Restriction endonuclease analysis. p A d H M 4 . p A d H M 4 - h A A T plasmid, or recombinant adenovims A d h A A T D N A was digested by Pad. Pad/HmdlU, Hindlll or 1-Ceul/Pl-Scd, separated in a 0.8% agarose gel, and ethidium bromide stained. Lane 1, I kb D N A ladder marker; Lane 2, Pod-digested p A d H M 4 plasmid D N A ; lane 3, PcfcI/W/ndlll-digested p A d H M 4 plasmid D N A ; lane 4, l-C<?Hl/Pl-5cfI-digested p A d H M 4 - h A A T plasmid D N A ; lane 5, Pod-digested p A d H M 4 - h A A T plasmid D N A ; lane 6, Pc(d////;!dIII-digested p A d H M 4 - h A A T plasmid D N A ; lane 7,1-Ccid/PI-Scd-digested A d h A A T (pool) viral D N A ; lane 8, //mdlll-digested A d h A A T (pool) viral D N A ; lane 9, ////tdlll-digested A d h A A T (clone I) viral D N A ; lane 10, /f//idIII-dige,sted A d h A A T (clone 2) viral D N A ; lane 11. //mdlll-digested A d h A A T (clone 3) Viral D N A ; lane 12, //;>7dlll-digested A d h A A T (clone 4) viral D N A ; lane 13, ////jdlll-digested A d h A A T (clone 5) viral D N A ; lane 14. //oidlll-digested A marker.
RESULTS
Construction and characterization of El-deleted adenovirus vector D N A
To constmct the plasmid with recombinant Ad vector DNA containing a foreign gene at the El deletion site by a single in vitro ligation, three unique restriction sites (I-C<?;(1, Swal. and PI-Scel) were introduced into the El deletion site of the vector plasmid containing a complete vector genome. l-Ceul (Mai'shall and Lemieux, 1991) and Pl-Scel (Gimble and Thomer. 1992) are intron-encoded endonucleases that recognize at least 9-10 and 11 bp, respectively. Swal is a rare-cutting resttiction enzyme with a sequence speciticity of 8 bp. The l-Cc((I and PI-5ceI sites were used for the insertion of foreign gene, while the Swal site was used to reduce the generation of parental, nonrecombined plasmid. The resulting vector plasmids, p A d H M 1, -2, -3, and -4, contain the complete Ad genome minus the El (pAdHMl, -3) or EI/E3 region (pAdHM2. -4), have Pod (pAdHM3. -4) or PacUClal (pAdHMI. -2) sites at both ends of the Ad genome, and have \-Ceul, Swal. and Pl-Scd sites in the El deletion site (Fig. I A). «//;dIIl and Pad treatment of p A d H M 4 produced the expected fragments shown in Fig. 2 (lanes 2 and 3).
A shuttle plasmid, p H M 3 , containing a pUC18-derived multicloning site between the I-Cc„I and PI-5c<?I sites was constmcted (Fig. IB) and used for cloning an expression cassette containing human a,-antitrypsin c D N A under the transcriptional control of the R S V LTR promoter (RSVhAATbPA); the
Dow
nloa
ded
by S
tanf
ord
Uni
vers
ity M
edic
al C
ente
r fr
om w
ww
.lieb
ertp
ub.c
om a
t 10/
09/1
8. F
or p
erso
nal u
se o
nly.
EFFICIENT CONSTRUCTION OF Ad VECTORS 2581
MOI
Table 1. Human al-Antitrypsin Expression IN HeLa Cells Infected with AdhAAT"
hAAT concentration (\i,g/dish/24 hr)
20 100
2.44 12.6
0.65 0.8
"HeLa cells were infected with AdhAAT (MOIs of 20 and 100), and h A A T concentration in the medium was determined 48 hr postinfection. Data represent means ± SD for four experiments.
product was called pHM3-hAATl. The cortesponding Ad vector DNA, pAdHM4-hAAT (Fig. IC), was produced by in vitro ligation of I-Ce«I/PI-SceI-digested p A d H M 4 and pHM3-hAATl (Fig. IC). l-Ceul and Pl-Scel digestion of pAdHM4-hAAT produced the expected 2.1-kb D N A fragment corresponding to an h A A T expression cassette in addition to the expected adenoviral fragments (Fig. 2, lane 4). The expected D N A fragments were also detected with either Pad or PadlHindlll digestion (Fig. 2, lanes 5 and 6). More than 9 0 % (15 of 16 clones) of the transformants had the cortect restriction pattem.
Generation of adenovirus vector expressing hAAT
To demonstrate that pAdHM4-hAAT was able to produce A d vector in 293 cells. Pad-linearized p A d H M 4 - h A A T D N A
was transfected into 293 cells and the cells were cultured for 10 days. The cell lysates were used to infect fresh 293 cells, followed by routine adenovims preparation. The cortectness of the viral D N A was verified by double digestion with l-Ceul and PI-5ceI (Fig. 2, lane 7) or Hindlll digestion (Fig. 2, lane 8) and found to have the same pattem as PacI///indIII-digested p A d H M 4 - h A A T plasmid D N A . For further confirmation, 17 independent plaques were found to have identical D N A restriction pattems (results for 5 clones are shown in Fig. 2, lanes 9-13). V i m s was not produced by the transfection of circular plasmid ( p A d H M 4 - h A A T ) into 293 cells, consistent with previous reports (Chartier et al, 1996; H e et al, 1998). Finally, to confirm the functionality of the vector, robust h A A T expression was detected in AdhAAT-infected H e L a cells (Table 1).
D I S C U S S I O N
We have developed a simple and efficient method for constmcting recombinant El-deleted adenoviral vectors by in vitro ligation. Previously, it has been difficult to manipulate A d D N A in vitro because of the paucity of unique useful restriction sites. Thus, by insertion of unique l-Ceul, Swal, and Pl-Scel sites in the El-deleted region of the plasmid with an El-deleted A d genome, w e could easily produce a vector by a simple in vitro ligation. The shuttle plasmid p H M 3 , which has multicloning sites between the 1-Ceul and PI-5ceI sites, allowed for the gene of interest to be easily introduced into the El deletion region
Method of Mizuguchi and Kay Method of Chartier et al.
Vector plasmid (e.g. pAdHM4)
>!' I-Ceul and Pl-Scel
digestion
Shuttle plasmid (e.g. pHM3)
Insert gene of Interest
Vector plasmid (e.g. pTG3602) Clal digestion
\ ^ < 2-3 l-Ceul and Pl-Scel
digestion /
ligation (Swal digestion)
Transformation into DHSa ^ ^ 3-4 days
Preparation of plasmid and restriction anaiysis
>!< Plasmid containing recombinant Ad virus
genome ^ • S-7 days
Pad digestion Transfection
Into 293 ceiis
days
Plaques •15-20 days (Almost all the plaques have the expected recombinant virus)
\
Shuttle plasmid
insert gene of interest ^ <•••
Linearization by cutting with
restriction enzyme
' 2-3 days
Transformation intoBJ5183
Preparation of plasmid >!'
Transformation Into standard strain of E.coil Preparation of plasmid and restriction analysis Plasmid containing recombinant Ad virus
genome Pad digestion
Transfection into 293 cells
^ 4 Plaques T"
(Almost all the plaques have the expected recombinant virus)
• 3-4 days
Method of Bett et al. Vector plasmid Shuttie plasmid (e.g. pBHGIO) (e.g. pAEIsplA) V ^
\ Insert gene \ of interest \ / • 2-3 days Transfection into 293 ceiis
^ ^ 2-4 days Plaques •••" 12-17 days
(Some plaques have wild type Ad virus. Need to amplify > .... 1*^^°'^°'^ and analyze the virus trom ^ additional each plaque) "* • 5-6 days
• 7-9 days
•17-22 days
F I G . 3. A comparison flow chart of the in vitro ligation and homologous recombination methods in E. coli or 293 cells.
Dow
nloa
ded
by S
tanf
ord
Uni
vers
ity M
edic
al C
ente
r fr
om w
ww
.lieb
ertp
ub.c
om a
t 10/
09/1
8. F
or p
erso
nal u
se o
nly.
2582 MIZUGUCHI AND KAY
of the vector. The Swal site of the vector plasmid nearly eliminated the possibility of generating a null cassette (nontrans-gene)-containing vector owing to the presence of the parental plasmid D N A .
The conventional in vitro ligation method (Berkner and Sharp, 1983; Gtiardi et al, 1990; Rosenfeld et al, 1991) has a number of disadvantages. Recombinant D N A cannot be recovered as a plasmid, because the viral D N A is used as a vector and the ligation products are directiy transfected into 293 cells. Therefore, in addition to the low efficiency, there is the generation of null vector and wild-type vims because of incomplete digestion and/or religation of the D N A s .
Although several other improved methods to make recombinant A d vectors have been reported (Bett et al, 1994; Chartier et al, 1996; Miyake et al, 1996; Crouzet et al, 1997; Fu and Deisseroth, 1997; He et al, 1998), they are based on inefficient homologous recombination in 293 cells (Bett et al, 1994; Miyake et al, 1996) or require additional steps. Miyake et al. (1996) reported an efficient method of vector production based on homologous recombination in 293 cells, but this required an extra step of A packaging and wild-type adenoviral genome generation was observed. The homologous recombination method in yeast (Ketner et al, 1994) and E. coli (Chartier et al, 1996; Crouzet et al, 1997; He et al, 1998) is probably as efficient in terms of recombinant viral production as the method described here; however, the E. coli system requires a three-step transformation, including the use of two different E. coli strains. This system does allow easy insertion of foreign genes into the E3 region as well as the El region. A cosmid A d vector plasmid cloning strategy requires an additional A packaging step (Fu and Deisseroth, 1997). A flow chart comparing the properties ofthe different homologous recombination systems is shown in Fig. 3.
The major advantage of our system is its simplicity; it requires only a routine two-step transformation protocol that is familiar to any molecular biologist. Because of the paucity of generation of wild-type or null vectors, the time-consuming plaque purification procedure is not absolutely required to produce vims. Furthermore, the system will allow for the easy modification of vector D N A backbone, or for addition of various expression cassettes, by routine cloning because of the many unique restriction sites in p A d H M l and p A d H M 2 . These include P o d (left end ofthe genome); 1-Ceul, Swal, and PI-5ceI; Xcal (bp 5764, in the case of p A d H M 2 ) ; Pmel (bp 13255); BamHI (bp 21562); Spel (bp27082); Srfl (bp 27527); and CZal (right end of the genome). In addition, this system may allow for the production of vectors that have proven difficult to make because they produce a protein that interferes with D N A recombination, or because they reduce cell viability because of their prolonged expression in mammalian cells. In general, the use of this system should facilitate the constmction of additional Ad vectors for gene transfer in basic research as well as gene therapy.
ACKNOWLEDGIVIENTS
We thank Leonard Meuse for technical assistance and Andre Lieber for helpful discussion. H.M. is the recipient of a fel
lowship from the Japan Society for the Promotion of Science. This work was supported by N I H DK49022.
REFERENCES
BERKNER, K.L., and SHARP, P.A. (1983). Generation of adenovirus by ttansfection of plasmids. Nucleic Acids Res. 11, 6003-6020.
BETT, A.J., H A D D A R A , W., PREVEC, L., and G R A H A M , F.L. (1994). An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc. Nati. Acad. Sci. U.S.A. 91, 8802-8806.
CHARTIER, C, DEGRYSE, E., GANTZER, M., DIETERLE, A„ PAVIRANI, A., and MEHTALI, M. (1996). Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coll J. Virol. 70, 4805^810.
CROUZET, J., NAUDIN, L., ORSINI, C, VIGNE. E., FERRERO, L., LE ROUX, A., BENOIT, P., LATTA, M., TORRENT, C, BRANELLEC, D., DENEFLE, P., M A Y A U X , IF., PERRICAUDET, M., and YEH, P. (1997). Recomblnational construction in Escherichia coli of infectious adenoviral genomes. Proc. Nati. Acad. Sci. U.S.A. 94, 1414-1419.
FU, S., and DEISSEROTH, A.B. (1997). Use ofthe cosmid adenoviral vector cloning system for the in vitro construction of recombinant adenoviral vectors. Hum. Gene Ther. 20, 1321-1330.
GILARDI, P., COURTNEY, M.. PAVIRANI, A., and PERRICAUDET, M. (1990). Expression ofhuman alpha 1-antitrypsin using a recombinant adenovirus vector. FEBS Lett. 267, 60-62.
GIMBLE, F.S., and THORNER, J. (1992). Homing of a D N A endonuclease gene by meiotic gene conversion in Saccharomyces cerevisiae. Nature (London) 357, 301-306.
HE, T.C, ZHOU, S., D A COSTA, L.T., YU, J., KINZLER, K.W., and VOGELSTEIN, B. (1998). A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. U.S.A. 95, 2509-2514.
KAY. M.A., and W O O . S.L. (1994). Gene therapy for metabolic disorders. Trends Genet. 19, 253-257.
KAY, M.A.. Ll, Q.. LIU, T.J., LELAND, F., T O M A N . C. FINEGOLD, M., and W O O , S.L.C. (1992). Hepatic gene therapy: Persistent expression of human alpha 1 -antitrypsin in mice after direct gene delivery in vivo. Hum. Gene Ther. 3, 641-647.
KAY, M.A., G R A H A M , F., LELAND. F., and W O O , S.L.C. (1995). Therapeutic serum concentrations of human alpha 1-antitrypsin after adenoviral-mediated gene transfer into mouse hepatocytes. Hepatology 21, 815-819.
KETNER, G., SPENCER, F., TUGENDREICH, S.. CONNELLY, C, and HIETER, P. (1994). Efficient manipulation ofthe human adenovirus genome as an infectious yeast artificial chromosome clone. Proc. Nati. Acad. Sci. U.S.A. 91, 6186-6190.
KOZARSKY, K.F., and WILSON, J.M. (1993). Gene therapy: Adenovirus vectors. Curr. Opin. Genet. Dev. 3, 499-503.
LIEBER, A., HE, C.-Y., KIRILLOVA, I., and KAY, M.A. (1996). Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo. J. Virol. 70, 8944-8960.
MARSHALL. P., and LEMIEUX, C. (1991). Cleavage pattern of the homing endonuclease encoded by the fifth intron in the chloroplast large subunit rRNA-encoding gene of Chlamvdomonas eugametos. Gene 104, 241-245.
MIYAKE, S., MAKIMURA, M., KANEGAE. Y., HARADA, S., SATO, Y., TAKAMORI, K., TOKUDA, C, and SAITO. I. (1996). Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing
Dow
nloa
ded
by S
tanf
ord
Uni
vers
ity M
edic
al C
ente
r fr
om w
ww
.lieb
ertp
ub.c
om a
t 10/
09/1
8. F
or p
erso
nal u
se o
nly.
EFFICIENT CONSTRUCTION OF Ad VECTORS 2583
the full-length virus genome. Proc. Natl. Acad. Sci. U.S.A. 93, 1320-1324.
ROSENFELD, M.A., SIEGFRIED, W., YOSHIMURA, K., YONEYAMA, K., FUKAYAMA, M., STIER, L.E., PAAKKO, P.K., GILARDI, P., STRATFORD PERRICAUDET, L.D., PERRICAUDET, M., et al (1991). Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo. Science 252, 431^34.
Address reprint requests to; Dr. Mark A. Kay
Department of Pediatrics Stanford University School of Medicine
300 Pasteur Drive, Room G305A Stanford CA 94305
Received for publication June 3, 1998; accepted after revision September 9, 1998.
Dow
nloa
ded
by S
tanf
ord
Uni
vers
ity M
edic
al C
ente
r fr
om w
ww
.lieb
ertp
ub.c
om a
t 10/
09/1
8. F
or p
erso
nal u
se o
nly.